10 results about "Human pathogen" patented technology

Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (Burkholderia pseudomallei, Borrelia burgdorferi, Brucella melitensis, Chlamydia muridarum, Coxiella burnetii, Francisella tularensis, human Herpes virus 1 and 2, Mycobacterium tuberculosis, Plasmodium falciparum, and Vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.

A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mIl2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG / Il2rg KO / hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., S. typhi or M. tuberculosis is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.

Provided in the present invention are the uses of an HPK1 inhibitor in preparation of drugs for preventing and / or treating human diseases or symptoms caused by pathogen infection or related to pathogen infection, and in preparation of drugs for preventing and / or treating tumors. The HPK1 inhibitor is a compound represented by following general formula I, or pharmaceutically acceptable salts, stereoisomers, esters, prodrugs, solvates and deuterated compounds thereof.

The application discloses a primer probe combination for detecting a novel human circovirus, a kit and application thereof, and belongs to the technical field of biotechnology. In view of defects that existing detection methods of the novel human circovirus rely on metagenomic sequencing, are time-consuming, high in cost and difficult to realize accurate quantification, the application designs specific primers and TaqMan probes with fluorescent labels based on a conservative region of a replicase protein gene of the novel human circovirus, and the specific primers and the TaqMan probes have no cross reaction with other viruses of the circovirus genus (including porcine circovirus types 1-4 and the like) and other common human pathogens, and high-specificity detection can be realized. The kit comprises the primer probe combination, PCR reaction components, positive and negative quality control samples and quantitative standard samples, and has the advantages of simple operation, high sensitivity and high amplification efficiency, and provides an effective means for rapid and accurate quantification detection of the novel human circovirus, and can be applied to the fields of clinical sample detection, blood screening and epidemiological monitoring.

The present invention is directed to methods and devices for identification of pathogens, and more particularly to solid phase recombinase polymerase amplification (SP-RPA) methods and devices for massively multiplexed solid-phase isothermal identification of human pathogens from patient samples. The principal application for multiplexed solid-phase isothermal identification of human pathogens is point-of-care diagnostics.

The invention relates to the technical field of buffer solutions, and discloses a chemiluminescence probe conditioning buffer solution and a preparation method thereof, the chemiluminescence probe conditioning buffer solution comprises the following raw materials by mass: 5%-10% of animal serum, 0.1%-0.5% of a chelating agent, 0.8%-1.5% of an electrolyte, 0.05%-0.2% of a preservative, 0.02%-0.1% of a surfactant, and the balance deionized water; the animal serum is one of inactivated bovine serum, sheep serum or rabbit serum and is used for replacing human plasma to reduce the risk of biological exposure, the chelating agent is citrate or an aminocarboxylic acid compound, the electrolyte is chloride of alkali metal or alkaline earth metal, and the preservative is one of isothiazolinone, saccharide or azide. The animal serum is used for replacing traditional human plasma to serve as a core component, the biological exposure risk caused by non-thorough inactivation of human-derived pathogens is thoroughly avoided from the raw material source, the use safety of the product is remarkably improved, and the core potential safety hazard of an existing product is solved.

The invention belongs to the technical field of biology, and particularly relates to a scrota-derived antibacterial peptide and application thereof. The antibacterial peptide from the scrota is SPC-1 or SPC-2, and the antibacterial peptide from the scrota is SPC-2; wherein the amino acid sequence of the SPC-1 is as shown in a sequence table SEQ ID NO. 1, and the amino acid sequence of the SPC-2 is as shown in a sequence table SEQ ID NO. 2. The scrota antibacterial peptide provided by the invention is novel in amino acid sequence, has remarkable antibacterial activity on gram-negative bacteria and gram-positive bacteria, shows broad-spectrum antibacterial property, and has the advantages of low hemolysis toxicity, low cytotoxicity and high safety, and by virtue of the characteristics, the scrota antibacterial peptide shows excellent antibacterial value; and a new resource is provided for the development of antibacterial products against the human pathogenic bacteria.

Genetically modified non-human animals expressing human SIRPα and human IL-15 from the non-human animal genome are provided. Also provided are methods for making non-human animals expressing human SIRPα and human IL-15 from the non-human animal genome, and methods for using non-human animals expressing human SIRPα and human IL-15 from the non-human animal genome. These animals and methods find many uses in the art, including, for example, in modeling human T cell and / or natural killer (NK) cell development and function, in modeling human pathogen infection of human T cells and / or NK cells, and in various in vivo screens.

The present invention relates to pure cultures of strains of the family Lactobacillaceae or of the genus Bifidobacterium as well as next-generation probiotic for use as antimicrobials for inhibiting growth of a bacterium, such as infectious bacteria or a bacterium under infections conditions. Furthermore, the present invention relates to a substance or composition comprising such substantially pure cultures of strains of the family Lactobacillaceae or of the genus Bifidobacterium or of a next-generation probiotic, as well as to methods of treating a bacterial infection in mammals by administering such strains of the family Lactobacillaceae or of the genus Bifidobacterium or of a next-generation probiotic.